Krakowski Program Wtórnej Prewencji Choroby Niedokrwiennej Serca. Realizacja wtórnej prewencji choroby niedokrwiennej serca w okresie po hospitalizacji w latach 1997/98 i 1999/2000.

Translated title of the contribution: Cracovian program for secondary prevention of ischemic heart disease. Secondary prevention of ischemic heart disease after discharge in 1997-98 and 1999-2000

Piotr Jankowski, Kalina Kawecka-Jaszcz, Andrzej Pajak, Grzegorz Bilo, Jacek S. Dubiel, Janusz Maciejewicz, Wiesław Piotrowski, Wanda Smielak-Korombel, Wiesława Tracz

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

INTRODUCTION: Although most actions undertaken within the scope of the secondary prevention of ischaemic heart disease should be initiated during hospitalization, obtaining maximal effects (quantified by cardiovascular risk reduction) depends largely on continuation and appropriate adjustment of these measures in the post-discharge period. The aim of this paper is to assess the implementation of guidelines on secondary prevention of ischaemic heart disease in the period after discharge from the hospital in the years 1999/2000 as compared with 1997/98. MATERIAL AND METHODS: In the first phase 515 subjects hospitalized in cardiac departments of university and general hospitals in Cracow were included. Out of them, 427 patients attended the control visit 6-18 months after index hospitalization. Based on a standardized questionnaire a structured medical history was obtained including the presence of risk factors and medication. At the same time body height and mass and blood pressure were measured and blood samples were obtained for lipid profile and fasting glucose level. RESULTS: Elevated cholesterol levels (> or = 5.2 mmol/l) were observed in 65.8% of patients in 1998/99 and 66.3% in 1999/2000, high blood pressure (> or = 140/90 mmHg) in 46.2% and 50.4%, obesity (BMI > or = 30 kg/m2) in 24.6% and 27.2%, fasting hyperglycemia (> or = 6.0 mmol/l) in 17.7% and 27.4% (p <0.05) and smoking in 16.3% and 15.9%, respectively. An increase was observed in the rate of antiplatelet (76.1% in 1998/99 vs 86.7% in 1999/2000, p <0.001) and lipid lowering drug use (34.0% vs 41.9%, p <0.05). The rate of beta-blockers and ACE inhibitors use did not change significantly. CONCLUSIONS: In the years 1999/2000 the control of main risk factors of ischaemic heart disease did not improve when compared with 1997/98. There was only an increase in the percentage of patients on antiplatelet and lipid lowering drugs. These results indicate that the dissemination of the guidelines for secondary prevention of ischaemic heart disease among physicians and patients remains one of the top priorities of cardiology in Poland.

Original languagePolish
Pages (from-to)142-146
Number of pages5
JournalPrzeglad Lekarski
Volume60
Issue number3
Publication statusPublished - 2003

Fingerprint

Secondary Prevention
Myocardial Ischemia
Lipids
Fasting
Hospitalization
Guidelines
Social Adjustment
Body Height
Poland
Risk Reduction Behavior
Hypercholesterolemia
Cardiology
Angiotensin-Converting Enzyme Inhibitors
General Hospitals
Hyperglycemia
Pharmaceutical Preparations
Obesity
Smoking
Blood Pressure
Hypertension

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Krakowski Program Wtórnej Prewencji Choroby Niedokrwiennej Serca. Realizacja wtórnej prewencji choroby niedokrwiennej serca w okresie po hospitalizacji w latach 1997/98 i 1999/2000. / Jankowski, Piotr; Kawecka-Jaszcz, Kalina; Pajak, Andrzej; Bilo, Grzegorz; Dubiel, Jacek S.; Maciejewicz, Janusz; Piotrowski, Wiesław; Smielak-Korombel, Wanda; Tracz, Wiesława.

In: Przeglad Lekarski, Vol. 60, No. 3, 2003, p. 142-146.

Research output: Contribution to journalArticle

Jankowski, P, Kawecka-Jaszcz, K, Pajak, A, Bilo, G, Dubiel, JS, Maciejewicz, J, Piotrowski, W, Smielak-Korombel, W & Tracz, W 2003, 'Krakowski Program Wtórnej Prewencji Choroby Niedokrwiennej Serca. Realizacja wtórnej prewencji choroby niedokrwiennej serca w okresie po hospitalizacji w latach 1997/98 i 1999/2000.', Przeglad Lekarski, vol. 60, no. 3, pp. 142-146.
Jankowski, Piotr ; Kawecka-Jaszcz, Kalina ; Pajak, Andrzej ; Bilo, Grzegorz ; Dubiel, Jacek S. ; Maciejewicz, Janusz ; Piotrowski, Wiesław ; Smielak-Korombel, Wanda ; Tracz, Wiesława. / Krakowski Program Wtórnej Prewencji Choroby Niedokrwiennej Serca. Realizacja wtórnej prewencji choroby niedokrwiennej serca w okresie po hospitalizacji w latach 1997/98 i 1999/2000. In: Przeglad Lekarski. 2003 ; Vol. 60, No. 3. pp. 142-146.
@article{7e8fe551bbf14175b57c9e33fd56f50d,
title = "Krakowski Program Wt{\'o}rnej Prewencji Choroby Niedokrwiennej Serca. Realizacja wt{\'o}rnej prewencji choroby niedokrwiennej serca w okresie po hospitalizacji w latach 1997/98 i 1999/2000.",
abstract = "INTRODUCTION: Although most actions undertaken within the scope of the secondary prevention of ischaemic heart disease should be initiated during hospitalization, obtaining maximal effects (quantified by cardiovascular risk reduction) depends largely on continuation and appropriate adjustment of these measures in the post-discharge period. The aim of this paper is to assess the implementation of guidelines on secondary prevention of ischaemic heart disease in the period after discharge from the hospital in the years 1999/2000 as compared with 1997/98. MATERIAL AND METHODS: In the first phase 515 subjects hospitalized in cardiac departments of university and general hospitals in Cracow were included. Out of them, 427 patients attended the control visit 6-18 months after index hospitalization. Based on a standardized questionnaire a structured medical history was obtained including the presence of risk factors and medication. At the same time body height and mass and blood pressure were measured and blood samples were obtained for lipid profile and fasting glucose level. RESULTS: Elevated cholesterol levels (> or = 5.2 mmol/l) were observed in 65.8{\%} of patients in 1998/99 and 66.3{\%} in 1999/2000, high blood pressure (> or = 140/90 mmHg) in 46.2{\%} and 50.4{\%}, obesity (BMI > or = 30 kg/m2) in 24.6{\%} and 27.2{\%}, fasting hyperglycemia (> or = 6.0 mmol/l) in 17.7{\%} and 27.4{\%} (p <0.05) and smoking in 16.3{\%} and 15.9{\%}, respectively. An increase was observed in the rate of antiplatelet (76.1{\%} in 1998/99 vs 86.7{\%} in 1999/2000, p <0.001) and lipid lowering drug use (34.0{\%} vs 41.9{\%}, p <0.05). The rate of beta-blockers and ACE inhibitors use did not change significantly. CONCLUSIONS: In the years 1999/2000 the control of main risk factors of ischaemic heart disease did not improve when compared with 1997/98. There was only an increase in the percentage of patients on antiplatelet and lipid lowering drugs. These results indicate that the dissemination of the guidelines for secondary prevention of ischaemic heart disease among physicians and patients remains one of the top priorities of cardiology in Poland.",
author = "Piotr Jankowski and Kalina Kawecka-Jaszcz and Andrzej Pajak and Grzegorz Bilo and Dubiel, {Jacek S.} and Janusz Maciejewicz and Wiesław Piotrowski and Wanda Smielak-Korombel and Wiesława Tracz",
year = "2003",
language = "Polish",
volume = "60",
pages = "142--146",
journal = "Przeglad Lekarski",
issn = "0033-2240",
publisher = "Fundacja Lekarzy Polskich-Pro-Medica",
number = "3",

}

TY - JOUR

T1 - Krakowski Program Wtórnej Prewencji Choroby Niedokrwiennej Serca. Realizacja wtórnej prewencji choroby niedokrwiennej serca w okresie po hospitalizacji w latach 1997/98 i 1999/2000.

AU - Jankowski, Piotr

AU - Kawecka-Jaszcz, Kalina

AU - Pajak, Andrzej

AU - Bilo, Grzegorz

AU - Dubiel, Jacek S.

AU - Maciejewicz, Janusz

AU - Piotrowski, Wiesław

AU - Smielak-Korombel, Wanda

AU - Tracz, Wiesława

PY - 2003

Y1 - 2003

N2 - INTRODUCTION: Although most actions undertaken within the scope of the secondary prevention of ischaemic heart disease should be initiated during hospitalization, obtaining maximal effects (quantified by cardiovascular risk reduction) depends largely on continuation and appropriate adjustment of these measures in the post-discharge period. The aim of this paper is to assess the implementation of guidelines on secondary prevention of ischaemic heart disease in the period after discharge from the hospital in the years 1999/2000 as compared with 1997/98. MATERIAL AND METHODS: In the first phase 515 subjects hospitalized in cardiac departments of university and general hospitals in Cracow were included. Out of them, 427 patients attended the control visit 6-18 months after index hospitalization. Based on a standardized questionnaire a structured medical history was obtained including the presence of risk factors and medication. At the same time body height and mass and blood pressure were measured and blood samples were obtained for lipid profile and fasting glucose level. RESULTS: Elevated cholesterol levels (> or = 5.2 mmol/l) were observed in 65.8% of patients in 1998/99 and 66.3% in 1999/2000, high blood pressure (> or = 140/90 mmHg) in 46.2% and 50.4%, obesity (BMI > or = 30 kg/m2) in 24.6% and 27.2%, fasting hyperglycemia (> or = 6.0 mmol/l) in 17.7% and 27.4% (p <0.05) and smoking in 16.3% and 15.9%, respectively. An increase was observed in the rate of antiplatelet (76.1% in 1998/99 vs 86.7% in 1999/2000, p <0.001) and lipid lowering drug use (34.0% vs 41.9%, p <0.05). The rate of beta-blockers and ACE inhibitors use did not change significantly. CONCLUSIONS: In the years 1999/2000 the control of main risk factors of ischaemic heart disease did not improve when compared with 1997/98. There was only an increase in the percentage of patients on antiplatelet and lipid lowering drugs. These results indicate that the dissemination of the guidelines for secondary prevention of ischaemic heart disease among physicians and patients remains one of the top priorities of cardiology in Poland.

AB - INTRODUCTION: Although most actions undertaken within the scope of the secondary prevention of ischaemic heart disease should be initiated during hospitalization, obtaining maximal effects (quantified by cardiovascular risk reduction) depends largely on continuation and appropriate adjustment of these measures in the post-discharge period. The aim of this paper is to assess the implementation of guidelines on secondary prevention of ischaemic heart disease in the period after discharge from the hospital in the years 1999/2000 as compared with 1997/98. MATERIAL AND METHODS: In the first phase 515 subjects hospitalized in cardiac departments of university and general hospitals in Cracow were included. Out of them, 427 patients attended the control visit 6-18 months after index hospitalization. Based on a standardized questionnaire a structured medical history was obtained including the presence of risk factors and medication. At the same time body height and mass and blood pressure were measured and blood samples were obtained for lipid profile and fasting glucose level. RESULTS: Elevated cholesterol levels (> or = 5.2 mmol/l) were observed in 65.8% of patients in 1998/99 and 66.3% in 1999/2000, high blood pressure (> or = 140/90 mmHg) in 46.2% and 50.4%, obesity (BMI > or = 30 kg/m2) in 24.6% and 27.2%, fasting hyperglycemia (> or = 6.0 mmol/l) in 17.7% and 27.4% (p <0.05) and smoking in 16.3% and 15.9%, respectively. An increase was observed in the rate of antiplatelet (76.1% in 1998/99 vs 86.7% in 1999/2000, p <0.001) and lipid lowering drug use (34.0% vs 41.9%, p <0.05). The rate of beta-blockers and ACE inhibitors use did not change significantly. CONCLUSIONS: In the years 1999/2000 the control of main risk factors of ischaemic heart disease did not improve when compared with 1997/98. There was only an increase in the percentage of patients on antiplatelet and lipid lowering drugs. These results indicate that the dissemination of the guidelines for secondary prevention of ischaemic heart disease among physicians and patients remains one of the top priorities of cardiology in Poland.

UR - http://www.scopus.com/inward/record.url?scp=1542703937&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=1542703937&partnerID=8YFLogxK

M3 - Articolo

C2 - 14575014

AN - SCOPUS:1542703937

VL - 60

SP - 142

EP - 146

JO - Przeglad Lekarski

JF - Przeglad Lekarski

SN - 0033-2240

IS - 3

ER -